Expert Perspectives on the Current State of Graft vs. Host Disease

Expert oncologists define graft vs host disease (GvHD) and discuss which risk factors might increase a patient’s risk of developing GvHD.

A brief review of the different regimens used by experts for GvHD prevention at their institutions and discuss the importance of GvHD Prevention.

Experts review the Phase III BMT CTN 1703 trial and share how the results of this trial might impact their practice and discuss the role of ATG and abatacept in their practice

A look into the future of acute GvHD prevention and discussing the impact of targeting specific organs to help manage GvHD prevention.

Experts discuss the clinical presentation, grading system and review treatment options for patients with acute GvHD.

An overview of steroid refractory acute GvHD and a review of the REACH trials that assessed the used of ruxolitinib in patients with GvHD.

Experts discuss new and exciting agents and combinations that are on the horizon for patients with acute GvHD.

Panel of oncologists define in chronic GvHD and review the typical presentation of a patient.

Comprehensive discussion into the available treatment options for patients that present with chronic GvHD.

Experts define and review treatment options for patients with chronic GvHD that are also steroid refractory.

A look into the future of chronic GvHD and which treatment options patients the panel is most excited about.

Experts share their insights and advice on how to best communicate with patients who are actively dealing with acute or chronic GvHD.